Viaderma

Viaderma Long-term Debt

Long-Term Debt of Viaderma (VDRM) as of Nov 3, 2026.

Long-term Debt

0.00USD

Last updated:

Long-Term Debt of Viaderma is 2024 0.00 USD. Long-Term Debt of Viaderma was 2023 0.00 USD. It decreases by % lower compared to the previous year.

The Viaderma Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2024
0.00 USD
The Viaderma Long-term Debt history
YEARLong-term DebtYoY
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viaderma Stock analysis

What does Viaderma do? ViaDerma, Inc. generates revenue through the manufacturing and sale of pharmaceutical products, primarily its lead product Vitastem, a topical antibiotic brand. The company sells Vitastem directly to local medical practitioners and patients in clinics within the Los Angeles area, focusing on treating various skin conditions. Additionally, ViaDerma licenses its proprietary transdermal delivery technology, which enables rapid transfer of active ingredients through the skin for immediate localized therapy. The company also develops products in anti-aging skin care, pain management, hair-loss, and toenail fungus, though these are not yet commercialized. ViaDerma, Inc. operates through its subsidiary ViaDerma, II Inc., which supports the development and commercialization of its product portfolio. The company's revenue streams include direct sales of Vitastem to healthcare providers and patients, as well as licensing fees from its transdermal technology. The primary market segments are medical practitioners and patients seeking treatments for skin ailments in the Los Angeles region, with future growth potential in emerging product categories like anti-aging and hair-loss solutions. The company's business model centers on proprietary technology that differentiates its products, allowing for faster and more effective treatment delivery. Vitastem is the cornerstone of its current revenue, while the transdermal technology serves as a complementary asset for both current and future product lines. This approach enables ViaDerma to target specific medical needs with localized solutions, primarily in the Los Angeles market, while expanding into new therapeutic areas through its pipeline. Viaderma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viaderma stock

On Eulerpool you can find the complete historical development of Long-Term Debt Viaderma since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Viaderma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Viaderma

All Key Metrics — Viaderma